基本信息
文件名称:Ivosidenib-13C5-AG-120-sup-13-sup-C-sub-5-sub-生命科学试剂-MCE.pdf
文件大小:466.45 KB
总页数:1 页
更新时间:2025-05-24
总字数:约2.65千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Ivosidenib-13C5

Cat.No.:HY-18767S2

Synonyms:AG-120-13C5

分?式:C????C?H??ClF?N?O?

分?量:587.92

作?靶点:Isotope-LabeledCompounds;IsocitrateDehydrogenase(IDH)

作?通路:Others;MetabolicEnzyme/Protease

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Ivosidenib-13C5(AG-120-13C5)是13C标记的Ivosidenib.Ivosidenib(AG-120)是异柠檬酸脱氢酶1的突变体

酶(mIDH1enzyme)的?服活性抑制剂,它使d-2-hydroxyglutatrate(2-HG)在体内降低。Ivosidenib具有良

好的的安全性和临床活性,具有AML研究的潜?。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubstitutiononthePharmacokineticsofPharmaceuticals.AnnPharmacother.2019;53(2):211-

216.

[2].Popovici-MullerJ,etal.